Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.
- DOI
- 10.1093/jjco/hyag128
- Published
- 2026 Aug 16
- Container
- Japanese journal of clinical oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/jjco/hyag128,
title = {Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.},
author = {Hirano K and Hata A and Yamanaka Y and Sumi T and Tamiya M and Sato Y and Oya Y and Hamai K and Katakami N and Iwasaki K and Uenishi T and Kokubo K and Igarashi A},
year = {2026},
journal = {Japanese journal of clinical oncology},
doi = {10.1093/jjco/hyag128},
url = {https://doi.org/10.1093/jjco/hyag128}
}RIS
TY - JOUR TI - Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes. AU - Hirano K AU - Hata A AU - Yamanaka Y AU - Sumi T AU - Tamiya M AU - Sato Y AU - Oya Y AU - Hamai K AU - Katakami N AU - Iwasaki K AU - Uenishi T AU - Kokubo K AU - Igarashi A PY - 2026 JO - Japanese journal of clinical oncology DO - 10.1093/jjco/hyag128 UR - https://doi.org/10.1093/jjco/hyag128 ER -
APA
K, H., A, H., Y, Y., T, S., M, T., Y, S., Y, O., K, H., N, K., K, I., T, U., K, K., & A, I. (2026). Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.. Japanese journal of clinical oncology. https://doi.org/10.1093/jjco/hyag128
Source records
- pubmed · retrieved 2026-09-26T06:29:02.292Z